Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.87
FGEN's Cash to Debt is ranked lower than
73% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. FGEN: 1.87 )
Ranked among companies with meaningful Cash to Debt only.
FGEN' s Cash to Debt Range Over the Past 10 Years
Min: 0.43  Med: 1.56 Max: 1.87
Current: 1.87
0.43
1.87
Equity to Asset 0.38
FGEN's Equity to Asset is ranked lower than
81% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. FGEN: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
FGEN' s Equity to Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.05 Max: 0.46
Current: 0.38
-0.3
0.46
F-Score: 3
Z-Score: 1.28
M-Score: -3.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -42.93
FGEN's Operating margin (%) is ranked higher than
54% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. FGEN: -42.93 )
Ranked among companies with meaningful Operating margin (%) only.
FGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -42.93  Med: -38.85 Max: -7.78
Current: -42.93
-42.93
-7.78
Net-margin (%) -47.44
FGEN's Net-margin (%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. FGEN: -47.44 )
Ranked among companies with meaningful Net-margin (%) only.
FGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -49.4  Med: -45.34 Max: -14.63
Current: -47.44
-49.4
-14.63
ROE (%) -40.67
FGEN's ROE (%) is ranked lower than
57% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. FGEN: -40.67 )
Ranked among companies with meaningful ROE (%) only.
FGEN' s ROE (%) Range Over the Past 10 Years
Min: -89.68  Med: -66.34 Max: -43
Current: -40.67
-89.68
-43
ROA (%) -17.65
FGEN's ROA (%) is ranked higher than
59% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. FGEN: -17.65 )
Ranked among companies with meaningful ROA (%) only.
FGEN' s ROA (%) Range Over the Past 10 Years
Min: -17.98  Med: -15.25 Max: -5.31
Current: -17.65
-17.98
-5.31
ROC (Joel Greenblatt) (%) -57.06
FGEN's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. FGEN: -57.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -57.05  Med: -36.93 Max: -3.35
Current: -57.06
-57.05
-3.35
» FGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

FGEN Guru Trades in Q1 2015

Joel Greenblatt 40,955 sh (New)
» More
Q2 2015

FGEN Guru Trades in Q2 2015

Joel Greenblatt Sold Out
» More
Q3 2015

FGEN Guru Trades in Q3 2015

Joel Greenblatt 29,283 sh (New)
Paul Tudor Jones 9,960 sh (New)
» More
Q4 2015

FGEN Guru Trades in Q4 2015

Paul Tudor Jones Sold Out
Joel Greenblatt 11,563 sh (-60.51%)
» More
» Details

Insider Trades

Latest Guru Trades with FGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.81
FGEN's P/B is ranked lower than
72% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. FGEN: 5.81 )
Ranked among companies with meaningful P/B only.
FGEN' s P/B Range Over the Past 10 Years
Min: 4.36  Med: 7.25 Max: 10.81
Current: 5.81
4.36
10.81
P/S 6.02
FGEN's P/S is ranked higher than
65% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. FGEN: 6.02 )
Ranked among companies with meaningful P/S only.
FGEN' s P/S Range Over the Past 10 Years
Min: 5.85  Med: 8.23 Max: 31.26
Current: 6.02
5.85
31.26
Current Ratio 2.99
FGEN's Current Ratio is ranked lower than
64% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. FGEN: 2.99 )
Ranked among companies with meaningful Current Ratio only.
FGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 3.08 Max: 3.83
Current: 2.99
2.23
3.83
Quick Ratio 2.99
FGEN's Quick Ratio is ranked lower than
61% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. FGEN: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
FGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.23  Med: 3.08 Max: 3.83
Current: 2.99
2.23
3.83
Days Sales Outstanding 31.09
FGEN's Days Sales Outstanding is ranked higher than
79% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. FGEN: 31.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
FGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.09  Med: 38.36 Max: 48.63
Current: 31.09
31.09
48.63

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.79
FGEN's Price/Tangible Book is ranked lower than
64% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. FGEN: 5.79 )
Ranked among companies with meaningful Price/Tangible Book only.
FGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.29  Med: 8.97 Max: 10.64
Current: 5.79
7.29
10.64
Price/Median PS Value 0.73
FGEN's Price/Median PS Value is ranked higher than
63% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. FGEN: 0.73 )
Ranked among companies with meaningful Price/Median PS Value only.
FGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 1.34  Med: 2.18 Max: 3.01
Current: 0.73
1.34
3.01
Earnings Yield (Greenblatt) (%) -7.79
FGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
52% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. FGEN: -7.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -9.26  Med: 0.00 Max: 0
Current: -7.79
-9.26
0

More Statistics

Revenue(Mil) $181
EPS $ -1.52
Short Percentage of Float7.17%
52-Week Range $14.38 - 31.90
Shares Outstanding(Mil)62.07

Analyst Estimate

Dec17 Dec18
Revenue(Mil) 205 167
EPS($) -0.49 -1.41
EPS without NRI($) -0.49 -1.41

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:1FG.Germany, FGEN.Mexico,
FibroGen Inc was incorporated in 1993 in Delaware. It is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Company's focus in the areas of fibrosis and hypoxia-inducible factor biology has generated multiple programs targeting various therapeutic areas. Its product candidate, roxadustat, or FG-4592, is an oral small molecule inhibitor of HIF prolyl hydroxylases ("HIF-PHs"), in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). FG-3019 is the Company's monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer and liver fibrosis. The Company's business area includes Europe and Japan. Certain of the components of its product candidates are acquired from single-source suppliers and have been purchased without long-term supply agreements. The Comapny do not have an alternative supplier of certain components of their product candidates. The Company faces competition from multiple other pharmaceutical and biotechnology companies, many of which have greater financial, technical and human resources and experience in product development, manufacturing and marketing. Its trademarks include "FibroGen". The clinical testing, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import, export and marketing, among other things, of its product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for FGEN

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016 May 02 2016
FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016 May 02 2016
ETF’s with exposure to FibroGen, Inc. : April 29, 2016 Apr 29 2016
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : April 28, 2016 Apr 28 2016
Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before... Apr 20 2016
Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before... Apr 20 2016
FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 01 2016
FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : March 24, 2016 Mar 24 2016
FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : March 23, 2016 Mar 23 2016
ETF’s with exposure to FibroGen, Inc. : March 22, 2016 Mar 22 2016
FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat... Mar 11 2016
FibroGen, Inc. :FGEN-US: Earnings Analysis: 2015 By the Numbers Mar 07 2016
FIBROGEN INC Financials Mar 05 2016
Edited Transcript of FGEN earnings conference call or presentation 29-Feb-16 9:30pm GMT Mar 01 2016
FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 29 2016
FibroGen Inc Earnings Call scheduled for 4:30 pm ET today Feb 29 2016
FibroGen Announces Fiscal 2015 Financial Results Feb 29 2016
Q4 2015 FibroGen Inc Earnings Release - After Market Close Feb 29 2016
Healthcare Stocks to Remedy any Portfolio – BCRX, ANAC, ALDR, and FGEN Feb 24 2016
FibroGen to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016 Feb 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK